Outer surface protein E antibody response and its effect on complement factor H binding to OspE in Lyme borreliosis

Panelius, Jaana; Meri, Taru; Seppälä, Ilkka; Eholuoto, Miia; Alitalo, Antti; Meri, Seppo

doi:10.1016/j.micinf.2007.10.016

Cited by 10 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, neuroinvasive B. garinii, the leading cause of neuroborreliosis, can express FH-binding proteins in vivo, thereby contributing its virulence [65]. Expression of OspE in vivo in borreliosis patients has also been concluded from the fact that neuroborreliosis patients with B. garinii infections have generated antibodies against OspE [66]. Furthermore, the anti-OspE antibodies are capable of preventing FH binding to the borrelial surfaces.…”

Section: Ospe Expressionmentioning

confidence: 99%

Complement evasion strategies of Borrelia burgdorferi sensu lato

2020

Self Cite

View full text Add to dashboard Cite

Borreliosis (Lyme disease) is a spirochetal disease caused by the species complex of Borrelia burgdorferi transmitted by Ixodes spp. ticks. Recorded to be the most common tick-borne disease in the world, the last two decades have seen an increase in disease incidence and distribution, exceeding 360 000 cases in Europe alone. If untreated, infection may cause skin symptoms, arthritis, and neurological or cardiac complications. Borrelia spirochetes have developed strategies to evade the mammalian host immune system. These include the complement system, which is an important first-line defense mechanism against invading microbes. To evade the complement, spirochetes bind soluble complement regulators factor H (FH), factor H-like protein, and C4bp to their outer surfaces. B. burgdorferi spirochetes can inhibit the classical pathway of complement by the outer surface protein (Osp) BBK32, which blocks the activation of the C1 complex, composed of C1q, C1r, and C1s. The FH-binding proteins of borreliae include Osps OspE, CspA, and CspZ. Following repeated infections, antibodies against these proteins develop and may provide functional immunity against borreliosis. This review discusses critical immune evasion strategies, focusing on complement evasion by borreliae.

show abstract

Section: Ospe Expressionmentioning

confidence: 99%

Complement evasion strategies of Borrelia burgdorferi sensu lato

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Unfortunately, many Borrelia strains can escape this by avoiding complement-mediated lysis via the Borrelia outer surface protein E (OspE). 17 The specific adaptive immune response against B. burgdorferi s.l. involves both humoral and cellular immune responses; both T-cell-dependent and T-cell independent immune responses lead to the production of Borrelia- specific antibodies that play an important role in the elimination of B.burgdorferi.…”

Section: Discussionmentioning

confidence: 99%

“… 19,20 In addition, other Borrelia proteins, including, the variable surface antigen (VlsE), basic membrane protein A (BmpA), decorin binding protein A and B (DbpA, DbpB), fibronectin-binding protein (BBK32), OspA, OspB and OspE are known to elicit antibody responses in natural infections. 17,20-22 Several of these antigens have proven to be useful in serologic tests for diagnosis of Lyme borreliosis. In a recent study, OspC IgM and VlsE IgG had the highest diagnostic value in patients with Lyme borreliosis.…”

Section: Discussionmentioning

confidence: 99%

“…Borrelia can avoid attack by specific antibodies by the induction of resistance to the complement system, by changing the expression of the surface proteins or by antigenic variation. 17,25-27 On the other hand immunity, especially T cell immunity, against Borrelia may contribute to Lyme disease pathology, such as myocarditis and arthritis. 28 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination against Lyme disease: Are we ready for it?

Kaaijk

Luytjes

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Lyme disease is the most common tick-borne illness in the Northern hemisphere and is caused by spirochetes of the Borrelia burgdorferi sensu lato complex. A first sign of Borrelia infection is a circular skin rash, erythema migrans, but it can develop to more serious manifestations affecting skin, nervous system, joints, and/or heart. The marked increase in Lyme disease incidence over the past decades, the severity of the disease, and the associated high medical costs of, in particular, the persistent forms of Lyme disease requires adequate measures for control. Vaccination would be the most effective intervention for prevention, but at present no vaccine is available. In the 1990s, 2 vaccines against Lyme disease based on the OspA protein from the predominant Borrelia species of the US showed to be safe and effective in clinical phase III studies. However, failed public acceptance led to the demise of these monovalent OspA-based vaccines. Nowadays, public seem to be more aware of the serious health problems that Lyme disease can cause and seem more ready for the use of a broadly protective vaccine. This article discusses several aspects that should be considered to enable the development and implementation of a vaccine to prevent Lyme disease successfully.

show abstract

“…All five types of CRASPs were identified also in B. afzelii and they were similarly designated BaCRASP 1-5. In B. garinii, paralogs of CRASPs were found, but it seems that they lack the affinity for factor H (Kraiczy et al 2001a;Panelius et al 2008;Wallich et al 2005).…”

Section: Ricinusmentioning

confidence: 99%

Prevention of Lyme Disease: Promising Research or Sisyphean Task?

Křupka

Zachová

Weigl

et al. 2011

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Borrelia burgdorferi sensu lato (Spirochaetes) is a group of at least 12 closely related species, some of which are responsible for chronic zoonotic infection that may cause Lyme disease. The only experimentally confirmed vector transmitting Borrelia to mammals is the Ixodes ticks. Borrelia is a highly adapted pathogen that can survive in the host organism in spite of the intense immune responses. Some patients have chronic long-lasting complications despite antibiotic therapy, probably due to adverse effects of the immune responses. A preventive vaccine against this bacterium has not been available due to the relatively broad spectrum and antigenic variability of Borrelia-surface lipoproteins and the different epitope recognition by experimental animals and humans. Although a human vaccine was marketed in the USA, it has been already pulled off the market. In addition, this vaccine was effective only in the USA, where the only pathogenic species is B. burgdorferi sensu stricto. Recent data indicate that a broadly effective vaccine will to be composed of a mixture of several antigens or multiple epitopes.

show abstract

Outer surface protein E antibody response and its effect on complement factor H binding to OspE in Lyme borreliosis

Cited by 10 publications

References 26 publications

Complement evasion strategies of Borrelia burgdorferi sensu lato

Complement evasion strategies of Borrelia burgdorferi sensu lato

Vaccination against Lyme disease: Are we ready for it?

Prevention of Lyme Disease: Promising Research or Sisyphean Task?

Contact Info

Product

Resources

About